Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Pharma Signs 40+ AI Deals Valued up to bn Each to Cut R&D Costs, Boursorama Says

Pharma Signs 40+ AI Deals Valued up to $12bn Each to Cut R&D Costs, Boursorama Says

November 19, 2026 Business Desk Business

Pharmaceutical companies signed more than 40 artificial intelligence partnerships between January 2025 and September 2026, with deal values ranging from $12 million upfront to $12 billion in cash, as the industry leans on AI to cut research costs and shorten development timelines, according to a compilation published by Boursorama.

The scale of the spending is the story. Boursorama’s tally shows upfront payments in the tens or hundreds of millions paired with milestone packages that stretch past $3 billion — Merck KGaA’s agreement with Valo Health, announced on November 20, 2025, carries potential payments exceeding that mark. Zonebourse, which covers the same market beat, frames the trend through the lens of individual drugmakers’ fundamentals rather than the deal count itself.

Two numbers capture the gap the industry is trying to close. Developing a new drug still takes roughly a decade and often more than $2 billion, which is why companies are paying nine-figure sums for platforms that promise to compress discovery and preclinical work. Against that backdrop, a $50 million upfront payment to an AI startup is cheap optionality.

Big pharma is buying in at every stage of the pipeline. Eli Lilly alone appears repeatedly in the record Boursorama compiled: a deal with Creyon Bio on April 29, 2025 ($13 million upfront, more than $1 billion in milestones), up to $1.3 billion with Superluminal Medicines in August 2025, a closed-loop AI-and-robotics discovery lab with NVIDIA worth up to $1 billion over five years in January 2026, and access to Insilico Medicine’s Pharma.AI platform in November 2025.

AstraZeneca moved from partnering to owning. After licensing oral drug candidates from CSPC Pharmaceutical in June 2025 — $110 million upfront against up to $3.6 billion in sales milestones — it acquired Modella AI outright in January 2026 to deploy foundation models across its oncology research.

Roche paid the largest confirmed upfront of the period: $750 million for PathAI, announced on May 7, 2026, with up to $300 million more in milestone payments, to convert manual pathology workflows into fully automated, AI-driven processes. Novartis took a different route, spending roughly $12 billion in cash to acquire Avidity Biosciences in October 2025 and strengthen its RNA and neuromuscular portfolio.

Partners Announced Deal value Aim
Pfizer × PostEra Jan 7, 2025 $610M potential; $12M upfront Pfizer AI lab; ADC payload design
AstraZeneca × CSPC Jun 13, 2025 $110M upfront; up to $3.6B sales milestones Oral drug candidates
Novartis × Avidity Oct 26, 2025 ~$12B cash xRNA, neuromuscular portfolio
Roche × PathAI May 7, 2026 $750M upfront; up to $300M milestones Digital pathology automation
Merck × Google Cloud Apr 22, 2026 Up to $1B over several years AI infrastructure, Gemini Enterprise
Novo Nordisk × Anthropic Sep 16, 2026 Undisclosed Claude models for drug discovery

The infrastructure layer is where the money is concentrating. Merck committed up to $1 billion to Google Cloud in April 2026 for AI infrastructure, engineers and a Gemini Enterprise licence, per Boursorama’s report. NVIDIA sits on the other side of at least eight deals, from IQVIA in January 2025 to Bristol Myers Squibb in July 2026, selling the computing power the platforms run on.

Deal structures have shifted, too. Early 2025 agreements were classic discover-and-license deals — Incyte paying Genesis Therapeutics $30 million upfront in February 2025 to use its GEMS platform for small-molecule design. By May 2026, Incyte extended that same collaboration with a $120 million upfront and more than $1 billion in potential milestones, Boursorama’s record shows. The renewal came at four times the original upfront price, within roughly fifteen months.

Not every arrangement is about molecules. Johnson & Johnson MedTech is using NVIDIA’s Isaac and Omniverse to simulate operating-room workflows. Kyndryl and Microsoft deployed Dragon Copilot to cut documentation burdens. Labcorp, AWS and Datavant built an AI-powered real-world data platform focused specifically on Alzheimer’s research, announced April 14, 2026.

Academic and philanthropic money is following the same direction. Oxford University secured £118 million from the Ellison Institute in September 2025 to map immune-correlates using AI, and the Gates Foundation put $200 million behind Anthropic public-benefit work in health and education in May 2026, per Boursorama’s compilation.

Zonebourse‘s coverage of the same theme takes a narrower framing, anchoring the story in one company’s revenue mix — Eli Lilly’s, with 74% of sales from endocrinology and 66.7% of revenue from the United States — rather than aggregating the deal flow. Boursorama’s piece is the broader ledger; zonebourse’s is the company-level view of why a firm with that concentration would spend heavily to widen its pipeline.

Where the reporting leaves things open: none of the sources provides evidence yet that these platforms have actually shortened a development timeline or produced an approved drug. The milestone payments are contingent by design, and most of the disclosed figures are ceilings, not commitments. The upfront cash — $12 million here, $120 million there, $750 million for PathAI — is what companies are paying for the possibility.

Eli Lilly, the company behind so many of these agreements, is an old hand at pharmaceutical firsts. Founded in 1876 in Indianapolis by Eli Lilly, a pharmaceutical chemist and Union army veteran of the American Civil War, it was the first company to mass-produce both insulin and the polio vaccine developed by Jonas Salk in 1955.

In November 2025 — the same month it signed on to Insilico Medicine’s Pharma.AI platform — it became the first health-care company in the world to reach a $1 trillion market capitalization, and it now ranks as the most valuable pharmaceutical company worldwide.

The next test arrives with the deals still running. Takeda’s agreement with Insilico, signed July 1, 2026, gives the Japanese drugmaker up to $600 million in potential payments plus royalties across its therapeutic areas; Novartis’s June 2026 deal with Orionis Biosciences carries a $40 million upfront against up to $1.4 billion in milestones for molecular-glue programs. Whether any of these structures delivers a candidate faster than the conventional path is the question the 2027 filings will answer.

More on this story: AI-Designed Drug Enters Final Human Trial Phase

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Keep reading

  • How Joni is Tackling Period Poverty Through Sustainable and Affordable Menstrual Care
  • Five Cascio Family Members Sue Jackson Estate Attorney Bryan Freedman Over 2019 Agreement
  • Inflation Since October 2024 Adds About $4,720 a Year to Household Costs (daybreakwire.com)
  • Silent Cancers: Why Some Types Develop Without Early Symptoms and Warning Signs (archyde.com)

Related

bourse de Paris, Boursorama, cotations, indices devises, investir, investissement, marché boursier, Sicav, trackers, warrants

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service